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ABSTRACT 27 
Cell motility and migration is a complex, multi-step, and multi-component process, intrinsic 28 
to progression and metastasis. Motility is dependent on the activity of integrin receptors and Rho-29 
family GTPases resulting in the remodelling of the actin cytoskeleton and formation of various 30 
motile actin-based protrusions. Merkel cell carcinoma (MCC) is an aggressive skin cancer with a 31 
high likelihood of recurrence and metastasis. Merkel cell polyomavirus (MCPyV) is associated with 32 
the majority of MCC cases, and MCPyV-induced tumourigenesis largely depends on the 33 
expression of the small tumour antigen (ST). Since the discovery of MCPyV, a number of 34 
mechanisms have been suggested to account for replication and tumourigenesis, but to date, little 35 
is known about potential links between MCPyV T antigen expression and the metastatic nature of 36 
MCC. Previously, we have described the action of MCPyV ST on the microtubule network and how 37 
this impacts on cell motility and migration. Here we demonstrate that MCPyV ST affects the actin 38 
cytoskeleton, to promote the formation of filopodia, through a mechanism involving the catalytic 39 
subunit of protein phosphatase 4 (PP4C). We also show that MCPyV ST-induced cell motility is 40 
dependent upon the activity of Rho-family GTPases Cdc42 and RhoA. In addition, our results 41 
indicate that the MCPyV ST-PP4C interaction results in the dephosphorylation of β1 integrin, likely 42 
driving the cell motility pathway. These findings describe a novel mechanism by which a tumour 43 
virus induces cell motility, which may ultimately lead to cancer metastasis and provides 44 
opportunities and strategies for targeted interventions for disseminated MCC.  45 
 46 
IMPORTANCE 47 
Merkel Cell Polyomavirus (MCPyV) is the most recently discovered human tumour virus. It 48 
causes the majority of cases of Merkel cell carcinoma (MCC), an aggressive skin cancer.  However, 49 
the molecular mechanisms implicating MCPyV-encoded proteins in cancer development are yet to 50 
be fully elucidated.  This manuscript builds upon our previous observations which demonstrate that 51 
the MCPyV ST antigen enhances cell motility, providing a potential link between MCPyV protein 52 
expression and the highly metastatic nature of MCC. Here we show that MCPyV ST remodels the 53 
actin cytoskeleton, promoting the formation of filopodia which is essential for MCPyV ST-induced 54 
cell motility and we also implicate the activity of specific Rho-family GTPases, cdc42 and RhoA in 55 
these processes. Moreover, we describe a novel mechanism for the activation of Rho GTPases 56 
and the cell motility pathway due to the interaction between MCPyV ST and the cellular 57 
phosphatase catalytic subunit PP4C, which leads to the specific dephosphorylation of β1 integrin. 58 
These findings may therefore provide novel strategies for therapeutic intervention for disseminated 59 
MCC.  60 
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INTRODUCTION 61 
Cell motility is a complex, multi-step and multi-component process. The actin cytoskeleton 62 
is an important contributor to cell motility and is required for the formation of several types of actin-63 
rich membrane protrusions (1). These protrusions contain actin filaments, which push the 64 
membrane forward leading to membrane deformation and extension. Actin filaments are formed by 65 
the polymerisation of globular monomeric actin (G-actin) into double stranded helical filamentous 66 
actin (F-actin), which is enhanced by the activity of several actin-binding proteins (2). Actin 67 
filaments can adopt different morphologies, such as filopodia and lamellipodia, depending on the 68 
number of filaments and the type and number of actin-binding proteins that associate with these 69 
filaments (2). Filopodia are thin, finger-like structures that are filled with tight parallel bundles of F-70 
actin. They have been described as 'antennae' or 'tentacles' that migrating cells use to probe their 71 
microenvironment, thus serving as pioneers during protrusion (3). In contrast, lamellipodia are thin 72 
sheet-like protrusions filled with a branched network of actin. In both cases, the fast-growing 73 
barbed ends of actin filaments are orientated towards the plasma membrane and the elongation of 74 
these protrusions pushes the leading edge forward, promoting cell migration (1). 75 
This complex cell motility process occurs via the remodelling of the actin cytoskeleton, 76 
which is controlled by the Rho-family GTPases, a large group of signalling molecules that act as 77 
signal mediators in the motility pathway. The Rho-family GTPases affect both the microtubule 78 
network and the actin cytoskeleton (4). Three of the most widely studied Rho-family GTPases are 79 
Cdc42, Rac1 and RhoA have all been implicated in the formation of actin containing plasma 80 
membrane protrusions. Cdc42 was originally implicated in filopodia formation (5), Rac1 in 81 
lamellipodia formation (6), and RhoA in stress fibre formation (7). While in many cases, this 82 
classification is still valid, recent research has shown that the functions of these Rho-family 83 
GTPases are intertwined, with cross-talk in the cell motility cascade, for example in filopodia 84 
formation (8). In addition to their important role in healthy cells, Rho-family GTPases also play a 85 
role in cancer development and metastasis (9-11). For instance, overexpression of RhoA has been 86 
observed in breast, colon, lung, and gastric cancers (12-14), amongst others. 87 
Rho-family GTPases are signal mediators and are central to the cell motility pathway. The 88 
pathway starts, however, with cellular receptors, such as the trans-membrane integrin receptors 89 
(15). They are αβ heterodimers, with human integrins having 24 types of α subunits and 9 types of 90 
β subunits, although some types are found in specific tissues (e.g. α3β2 in platelets (16)) while 91 
others are widely expressed (e.g. α5β1) (17). Integrins have large extracellular domains that bind 92 
the extracellular matrix (ECM) and link to the actin cytoskeleton through short cytoplasmic tails (18). 93 
Their main function is to transmit signals from the ECM to the cell interior. In addition, integrins play 94 
a well-recognised role in cancer progression (19). 95 
Cancers with high metastatic potential use the cell motility pathway to disseminate from the 96 
original tumour to distant secondary sites. One such cancer is Merkel cell carcinoma (MCC), a rare 97 
but aggressive malignancy of neuroendocrine origin that presents as reddish or purplish nodules 98 
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on sun-exposed areas of skin (20). The number of reported cases of MCC has tripled in the past 99 
20 years (21), and risk factors include advanced age, UV exposure, and immune suppression (20, 100 
22). MCC has a poor 5-year survival rate, characterised by local recurrence, early spread to local 101 
lymph nodes and high likelihood of forming distant metastases (20). 102 
Merkel cell polyomavirus (MCPyV) is a recently-discovered oncogenic virus that has been 103 
implicated as the causative agent of MCC in ~80% of cases in the north hemisphere (23). MCPyV 104 
infection is asymptomatic and ubiqitous in many populations, with up to 80% healthy adults 105 
infected (24). Like other polyomaviruses, MCPyV expresses the T antigen, whose spliced products, 106 
namely large T antigen and small T antigen (LT and ST), are required for viral replication and 107 
tumourigenesis (23). The mechanism for MCPyV tumourigenesis has been broadly established (23, 108 
25, 26), upon loss of immunosurveillance, due to old age or immunosuppression, the virus can 109 
integrate into the cellular genome. Integration occurs prior to clonal expansion of tumour cells (25). 110 
In addition to integration, another prerequisite for tumourigenesis is the truncation of MCPyV LT, as 111 
only the truncated form of this protein has been observed in MCPyV-positive MCC tumours. This is 112 
likely due to the fact that truncated MCPyV LT is replication deficient, as integrated MCPyV with a 113 
replication-competent MCPyV LT may initiate unlicenced replication which would ultimately lead to 114 
cytopathic cell death (26). The molecular mechanisms of the MCPyV life cycle and oncogenic 115 
properties have been extensively reviewed (27-31) . 116 
Both LT and ST are required for MCPyV-positive MCC cell survival and proliferation, and 117 
siRNA-mediated depletion of either leads to cell death (32). Taking SV40 as a model, MCPyV LT 118 
would be expected to be the main viral oncoprotein driving cellular transformation. However, in 119 
contrast to simian virus 40 (SV40), MCPyV LT cannot initiate cellular transformation (33), although 120 
it likely plays at least an accessory role, as it can bind to host factors that regulate cellular 121 
proliferation, such as the retinoblastoma protein (pRb) and Hsc70 (34). Conversely, MCPyV ST 122 
alone can transform rodent cells and induce serum-free proliferation of human cells, it is therefore 123 
considered to be the main transforming factor (33). However, there have been conflicting results on 124 
the contribution of MCPyV ST to MCPyV-positive MCC cell proliferation after initial transformation 125 
(35, 36), thus the role of MCPyV ST is not yet fully understood. What is known leads  to the 126 
conclusion that MCPyV ST is a multi-functional protein. It promotes the hyperphosphorylation of 127 
4E-BP1, deregulating cap-dependent translation (33), inhibits NF-B-dependent gene transcription 128 
through NEMO (37), targets the host ubiquitin ligase SCFFwb7, leading to the stabilisation of MCPyV 129 
LT and several host oncoproteins (38) and also promotes transcriptional changes in glycolytic 130 
metabolic pathways (39). Importantly, recent studies using a panel of preterm transgenic mice co-131 
expressing epidermis-targeted coexpression of ST and the cell fate-determinant atonal bHLH 132 
transcription factor 1 (ATOH1) lead to development of widespread cellular aggregates, with 133 
histology and marker expression mimicking human intraepidermal MCC, supporting the concept 134 
that ST is the major MCPyV-derived oncogenic driver in MCC (40).  135 
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MCC has a highly metastatic phenotype and correlates with poor MCC survival rates (41). 136 
This is also supported by recent studies showing that engraftment of MCC cell lines into SCID mice 137 
results in circulating tumour cells and metastasis formation (42). Aligned with this observation is 138 
that we have previously reported that MCPyV ST can enhance cell motility through microtubule 139 
dissociation. Expression of MCPyV ST upregulates the levels of stathmin, a microtubule-140 
associated protein, and leads to microtubule destabilisation, which is necessary for a migratory 141 
phenotype (43).  142 
Here we extend this analysis and show that MCPyV ST drives cell motility by disrupting the actin 143 
cytoskeleton. We demonstrate that MCPyV ST expression induces the formation of filopodia-like 144 
structures, through a mechanism dependent on the activity of the Rho-family GTPases Cdc42, 145 
RhoA, and, to a lesser extent, Rac1. This process is initiated by a MCPyV ST-PP4C interaction 146 
which results in the dephosphorylation of β1 integrin.    147 
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RESULTS 148 
MCPyV ST expression affects the levels of actin-associated proteins. Cell motility 149 
regulation is a complex, multi-step process, an important aspect of which is the regulation of the 150 
actin cytoskeleton and associated proteins. We have previously used a SILAC-based quantitative 151 
proteomics approach (44, 45), to determine alterations in the host cell proteome upon inducible 152 
MCPyV ST expression in a HEK-293-derived cell line, i293-ST (43). Results demonstrated that 153 
MCPyV ST expression led to the upregulation of the microtubule-associated protein, stathmin, 154 
which affects microtubule dissociation (46). Moreover, results highlighted that proteins which 155 
regulated the actin cytoskeleton were also altered upon MCPyV ST expression. These proteins 156 
include Cofilin-1, Cortactin and Actin-related proteins 2/3 complex subunits which were 157 
upregulated by 5.1, 3.7 and 3.9 fold respectively.  158 
To confirm increased levels of actin-associated proteins identified by the quantitative 159 
proteomic approach, i293-ST cells remained uninduced or were induced with doxycycline hyclate, 160 
or a MCPyV negative MCC cell line, MCC13 cells, transfected with EGFP or EGFP-ST. 161 
Immunoblotting of cell lysates confirmed an upregulation of actin-associated proteins Arp3, 162 
cortactin, and cofilin upon expression of MCPyV ST, both in i293-ST and in MCC13 cells (Fig. 1A). 163 
Densitometry showed a 4-fold increase in Arp3 in both cell lines, a 4-fold increase in i293-ST cells 164 
and a 3-fold increase in MCC13 cells of cortactin, and a 2-fold increase in i293-ST cells and a 4-165 
fold increase in MCC13 cells of cofilin (Fig. 1B). Comparing these values against control cells, a 166 
significant increase in actin-associated protein levels is observed in MCPyV ST-expressing cells. 167 
This increase in protein levels probably occurs at the transcriptional level, as RT-qPCR showed 168 
significant changes in the mRNA levels of Arp3, cortactin, or cofilin upon MCPyV ST expression in 169 
i293-ST cells (Fig. 1C), which correlates with recent results showing that MCPyV ST can 170 
dynamically alter the transcriptome of human cells (39). 171 
To investigate the differential expression of actin-associated proteins in the context of MCC, 172 
multicolour immunochemistry analysis was performed on formalin-fixed, paraffin-embedded 173 
(FFPE) sections of two primary MCC tumours. Sections were incubated with cortactin, cytokeratin 174 
20 (CK20) (a marker widely used to distinguish MCC) and a MCPyV LT (CM42B) specific 175 
antibodies. An isotyped-matched control was also used as a negative control. Results show 176 
increased levels of cortactin expression coincident with CK20 and LT staining in regions of both 177 
tumours (Fig. 1D). Moreover, immunoblot analysis was performed on the cellular lysates of two 178 
independent MCC tumour samples comparing protein levels against a negative control non-tumour 179 
cadaveric skin sample. Results again demonstrate an increase in cortactin and Arp3 protein levels 180 
in MCC tumour samples compared to control (Fig. 1E and 1F). Notably, higher levels of actin-181 
associated proteins were observed in MCC tumour sample 2 compared to MCC tumour sample 1, 182 
which correlates with higher levels of MCPyV ST in sample 2. Furthermore, immunoblot analysis 183 
was also performed on cellular lysates of the MCPyV-positive MCC cell line, WAGA, which were 184 
transduced with lentiviruses containing shRNA targeting ST or a scrambled control, as previously 185 
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described (33, 38). Results demonstrated that depletion of MCPyV ST led to a reduction in 186 
cortactin and Arp3 protein levels (Fig. 1G). Together these results demonstrate that levels of actin 187 
cytoskeleton-related proteins are altered upon MCPyV ST expression and in the context of MCC, 188 
implicating MCPyV ST in inducing cell motility and potentially MCC metastasis. 189 
 190 
MCPyV ST expression induces the formation of actin-based protrusions. 191 
Observations of altered actin-associated protein levels upon MCPyV ST expression suggested the 192 
possibility of actin cytoskeleton-related phenotypic changes. To examine any changes in MCPyV 193 
ST-expressing cells, HEK-293 cells were transfected with EGFP or EGFP-ST. Cells were then 194 
fixed and stained with rhodamine phalloidin, an actin-binding compound to investigate any possible 195 
changes in the actin cytoskeleton. MCPyV ST-expressing HEK-293 cells showed an abundance of 196 
actin-based protrusions, compared to the much smoother cell periphery of control EGFP-197 
expressing HEK-293 cells (Fig. 2A). Similar results were also observed in MCPyV ST-expressing 198 
MCC13 cells, showing an increased number of longer protrusions, although the difference in 199 
number was less pronounced. In addition, it was observed that MCC13 cells appeared to have 200 
more abundant levels of intracellular actin which may be due to the increase in actin-associated 201 
protein levels upon MCPyV ST expression (Fig. 2B). To quantify the increase in actin-based 202 
protrusions upon MCPyV ST expression, the protrusions were counted and their lengths measured 203 
using ImageJ software. Analysis showed an increase in the numbers and length of these actin-204 
based protrusions in MCPyV ST-expressing HEK-293 cells (Fig. 2C), and an increase in longer 205 
actin-based protrusions in MCPyV ST-expressing MCC13 cells (Fig. 2D). Comparing the average 206 
length of protrusions from this analysis, a significant increase in length was observed in MCPyV 207 
ST-expressing cells. To confirm the actin cytoskeleton-related phenotypic changes observed in 208 
HEK-293 and MCC13 cells, similar experiments were performed in primary epidermal 209 
keratinocytes (Fig. 2E and F) and primary human dermal fibroblast cells (Fig. 2G and H). Results in 210 
both primary cell lines show an increase in the number and length of actin-based protrusions upon 211 
MCPyV ST expression. In addition, immunofluorescence studies suggest an increase in 212 
intracellular actin levels upon McPyV ST expression. Together these observations suggest that 213 
MCPyV ST expression leads to phenotypic changes in the actin cytoskeleton resulting in the 214 
formation of actin-based protrusions. 215 
 216 
MCPyV ST expression induces the formation of filopodia. Visually, the thin, filamentous 217 
nature of the actin-based protrusions formed upon MCPyV ST expression appear to suggest that 218 
they are filopodia. However, to conclusively characterise and classify these protrusions, a number 219 
of actin-associated proteins were screened using immunofluorescence. HEK-293 cells were co-220 
transfected with Flag-tagged MCPyV ST (ST-flag) (37), in combination with one of the following 221 
GFP-tagged constructs: cortactin, N-WASP, mDia2 or fascin, or EGFP-ST and one of the following 222 
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myc-tagged constructs: IRSp53 or IRSTK. Cells were then fixed and stained with rhodamine 223 
phalloidin to visualise actin-based structures. 224 
Of particular interest were results utilising mDia2. In control cells, mDia2 was seen to be 225 
diffuse in the cytoplasm, while in cells expressing MCPyV ST, mDia2 relocalised to the cell 226 
periphery and into the actin-based protrusions (Fig. 3A). Similar results were observed for IRSp53, 227 
with this protein being observed to be diffuse in the cytoplasm in control cells but it relocalised to 228 
the cellular periphery and into the actin-based protrusions upon the expression of MCPyV ST (Fig. 229 
3B). No change in N-WASP or IRSTK could be observed upon MCPyV ST expression (data not 230 
shown). As both mDia2 (47) and IRSp53 (48) are associated with filopodia formation, this was the 231 
first marker-associated indication that MCPyV ST expression induced filopodia formation. To 232 
further confirm that MCPyV ST induced the formation of filopodia, an additional filopodia marker, 233 
myosin X, was utilised, as myosin X is localised to the tips of filopodia (49). To this end, HEK-293 234 
cells were transfected with EGFP or EGFP-ST and stained for myosin X. Punctate foci of myosin X 235 
staining can be observed at the tips of MCPyV ST-induced actin-based protrusions (Fig. 3C). 236 
Together, these results confirm that the protrusions induced by MCPyV ST expression are filopodia. 237 
 238 
The interaction between MCPyV ST and PP4C is important for inducing filopodia 239 
formation. We have previously shown the importance of the interaction between MCPyV ST and 240 
PP4C, with regards to MCPyV ST-induced cell motility using a deletion mutant of MCPyV, termed 241 
STΔ95-111. This MCPyV ST mutant ablates the interaction between MCPyV ST and protein 242 
phosphatase 2A (PP2A) Aβ and PP4C (43). We therefore investigated whether cellular 243 
phosphatases were required for MCPyV ST-induced filopodia formation. For this purpose, HEK-244 
293 cells were first transfected with either EGFP, EGFP-ST, EGFP-R7A (a previously described 245 
PP2A Aα non-binding mutant) or EGFP-95-111 (PP2A Aβ and PP4C non-binding mutant). Cells 246 
were then fixed and stained with rhodamine phalloidin to identify actin-based structures (Fig. 4A). 247 
Results suggest reduced filopodia formation upon the expression of EGFP-ST95-111 similar to 248 
EGFP control, whereas EGFP-R7A induces filopodia similar to EGFP-ST. Quantitative analysis of 249 
filopodia confirmed that while expression of the MCPyV STΔ95-111 deletion mutant did not induce 250 
filopodia, the expression of the MCPyV ST R7A mutant induced filopodia formation to similar levels 251 
as wild type ST(Fig. 4B). However, this analysis was not sufficient to determine which MCPyV ST-252 
phosphatase interaction was important in cell motility and filopodia formation, as the Δ95-111 253 
deletion affects the interaction of MCPyV ST with both PP2A Aβ and PP4C. 254 
Therefore, to conclusively determine which cellular phosphatase is responsible for MCPyV 255 
ST-induced cell motility and filopodia formation, additional alanine-scanning MCPyV ST mutants 256 
were utilised which distinguish the interaction between MCPyV ST and PP2A Aβ and PP4C, as 257 
previously characterised (50). However, these previous experiments utilised co-258 
immunoprecipitation assays over-expressing tagged versions of PP2A and PP4C. Therefore, 259 
herein we have repeated the co-immunoprecipitation experiments to examine the interaction of 260 
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MCPyV ST-GFP mutants with endogenous PP2A Aβ and PP4C, using GFP-TRAP pulldowns. 261 
Results show that wild type EGFP-ST interacts with both endogenous forms of PP2A Aβ and 262 
PP4C, in contrast EGFP-95-111 and EGFP-ST102A ablates both PP2A Aβ and PP4C binding, 263 
whereas EGFP-ST102A only disrupts the interaction with PP4C (Fig. 4C). Therefore, to determine 264 
which cellular phosphatase is responsible for MCPyV ST-induced cell motility HEK-293 or MCC13 265 
cells were transfected with either EGFP-ST102A, or EGFP-ST103A and cells imaged using the 266 
IncuCyte live cell imaging system (Fig. 4D). Cell motility was analysed using ImageJ software by 267 
tracing the tracks of individual cells, allowing quantification of the distance travelled, and results 268 
showed that in both cell lines expressing either EGFP-ST102A or EGFP-ST103A, a decrease in 269 
motility was observed in comparison to cells expressing EGFP-ST (p<0.001) (Fig. 4D). This 270 
suggests that the specific interaction of MCPyV ST with PP4C is required for MCPyV ST-induced 271 
cell motility. To confirm the association between MCPyV ST, PP4C, cell motility and filopodia 272 
formation, HEK-293 cells were transfected with EGFP-ST102A or EGFP-ST103A, fixed and 273 
stained with rhodamine phalloidin to observe actin-based structures (Fig. 4A). Together with 274 
quantitative analysis of filopodia formation (Fig. 4B), results showed that cells expressing EGFP-275 
ST102A and EGFP-ST103A showed a marked decrease in filopodia formation when compared to 276 
cells expressing EGFP-ST. Comparing the average length of protrusions from this analysis, a 277 
significant increase in length was observed in MCPyV ST and R7A-expressing cells compared to 278 
EGFP-ST95-111, 102A and 103-expressing cells. Together this suggests that PP4C is required 279 
for MCPyV ST-induced filopodia formation. To confirm these observations, filopodia formation was 280 
also analysed in the absence or presence of a PP4C transdominant phosphatase-dead mutant, 281 
PP4-RL (51). Analysis and quantification of rhodamine phalloidin stained cells showed a reduced 282 
number of longer actin-based protrusions in MCPyV ST-expressing cells in the presence of PP4-283 
RL (Fig. 4E and F). Again comparing the average length of protrusions from this analysis, a 284 
significant increase in length was observed in MCPyV ST-expressing cells alone compared to cells 285 
expressing PP4-RL. These results correlate with the data gathered from live cell imaging 286 
experiments and reveal the importance of the specific interaction of MCPyV ST with PP4C to 287 
induce cell motility and filopodia formation. 288 
 289 
MCPyV ST-induced cell motility is dependent on the action of Rho-family GTPases. 290 
The Rho-family GTPases are a superfamily of signalling molecules, some of which have been 291 
implicated in increased cell motility and metastasis in various cancers (9-11). There is also an 292 
undisputed role of the Rho-family GTPases in actin dynamics (52). Therefore to determine whether 293 
Rho-family GTPases are involved in MCPyV ST-induced cell motility, a selection of well 294 
characterised inhibitors targetting Rho-family GTPases were utilised at non-cytotoxic 295 
concentrations as measured by MTS assay (data not shown): ML141 (a Cdc42/Rac1 inhibitor), 296 
NSC23766 (a Rac1 inhibitor), Rhosin (a RhoA inhibitor) and ZCL278 (a Cdc42 inhibitor). 297 
Treatment of HEK-293-derived inducible cell lines, i293-EGFP and i239-EGFP-ST, along side 298 
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MCC13 cells, enabled visualisuation of cell motility in live cells. i293-EGFP and i293-EGFP-ST 299 
cells were induced using doxycycline hyclate, while MCC13 cells were transfected with EGFP or 300 
EGFP-ST, and treated with each respective inhibitor for 24 h. Cells were then imaged using the 301 
IncuCyte live cell imaging system, taking an image every 30 min for a 24-h period (Fig. 5A and C). 302 
Distances travelled by individual cells were tracked using ImageJ software. No significant 303 
differences were observed among the average distances travelled by control cells not expressing 304 
MCPyV ST, in both untreated and treated cells with the Rho-family GTPase inhibitors (Fig. 5B and 305 
D), demonstrating that the concentrations of inhibitors were non-toxic. In contrast, decreased cell 306 
motility upon treating MCPyV ST-expressing cells with both Cdc42 inhibitors and the RhoA inhibitor 307 
is clearly apparent (p<0.001), while no significant decrease was observed when cells are treated 308 
with the Rac1 inhibitor (Fig. 5B and D). This suggests a role for Cdc42 and RhoA GTPases in 309 
facilitating MCPyV ST-induced cell motility. 310 
 311 
MCPyV ST-induced filopodia formation is dependent on the activity of the Rho-family 312 
GTPases. It was also important to determine whether the observed effect of Rho-family GTPases 313 
on MCPyV ST-induced cell motility was mirrored in filopodia formation. HEK-293 cells were 314 
transfected with EGFP or EGFP-ST cells, and treated with the specific Rho-family GTPase 315 
inhibitors (ML141, NSC27366, Rhosin and ZCL278) for 24 h. Cells were then fixed and stained 316 
with rhodamine phalloidin to observe actin-based structures (Fig. 6A). Quantitative analysis of 317 
filopodia showed a decrease in filopodia formation when MCPyV ST-expressing cells were treated 318 
with Rho-GTPase inhibitors for Cdc42 and RhoA, however the Rac1 inhibitor showed little effect. 319 
(Fig. 6B). Comparing the average length of protrusions from this analysis, a significant increase in 320 
length was observed in MCPyV ST-expressing cells compared to cells treated with the Cdc42 and 321 
RhoA inhibitors. 322 
To further examine any differences on MCPyV ST-induced filopodia formation by Rho-323 
family GTPases, HEK-293 cells were co-transfected with ST-Flag and Rho-family GTPase 324 
transdominant mutants: pcDNA-5-GFP-Cdc42-T17N, pcDNA5-GFP-Rac1-T17N, or pcDNA5-GFP-325 
RhoA-T19N (Fig. 6C). These transdominant mutants are inactive and inhibit endogenous Cdc42, 326 
Rac1 and RhoA activity (53). Cells were then fixed and stained with rhodamine phalloidin to 327 
visualise actin-based structures. Quantitative analysis of filopodia showed a small decrease in 328 
filopodia upon co-expression of MCPyV ST with the Rac1 transdominant mutant; however, a 329 
marked reduction was observed when cells were co-transfected with either the Cdc42 or RhoA 330 
transdominant mutants, confirming the observation of the live cell imaging data (Fig. 6D). Again 331 
comparing the average length of protrusions from this analysis, a significant increase in length was 332 
observed in MCPyV ST-expressing cells compared to cells expressing the Cdc42 or RhoA 333 
transdominant mutants. This suggests a definitive role for Cdc42 and RhoA in MCPyV ST-induced 334 
filopodia formation. Consequently, we next aimed to directly measure the activity of Cdc42 and 335 
RhoA in MCPyV ST-expressing cells, employing an affinity precipitation assay to specifically 336 
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measure the amount of RhoA–GTP or Cdc42–GTP forms (54, 55). Transfected EGFP or EGFP-ST 337 
HEK-293 cell lysates were incubated with either PAK1 PBD or Rhotekin RBD Agarose beads, 338 
which selectively bind to the GTP-bound but not GDP-bound forms of Cdc42 and RhoA, 339 
respectively. The amount of active G protein was then detected by immunoblotting with Cdc42 and 340 
RhoA-specific antibodies. Expression of MCPyV ST resulted in elevated levels of active cdc42 and 341 
RhoA compared with control cells expressing GFP alone (Fig. 6E). Together these data further 342 
indicate that the Rho-family GTPases are involved in MCPyV ST-induced cell motility. 343 
 344 
The activity of integrins is important for MCPyV ST-induced cell motility. Herein and 345 
previously (43), we report the importance of the MCPyV ST-PP4C interaction in cell motility and 346 
filopodia formation. In order to uncover a potential role of PP4C in MCPyV ST-induced cell motility, 347 
i293-GFP and i293-GFP-ST cells were transfected with HA-Cdc42 or HA-Rac1, then induced for 348 
48 h. Cell lysates were probed for phosphorylated Cdc42/Rac1 (residue Ser 71) to determine if 349 
MCPyV ST expression affects the phosphorylation status of Rho-family GTPases. Surprisingly, 350 
results showed no change in the phosphorylation status of Cdc42/Rac1 (Fig. 7A) indicating that the 351 
MCPyV ST-PP4C interaction does not affect the phosphorylation status of Rho-family GTPases 352 
directly. Therefore, to uncover a possible target for the MCPyV ST-PP4C interaction, factors 353 
upstream of the Rho-family GTPases were investigated. Integrins are known to be important in 354 
various aspects of cell adhesion, polarity, and motility, where they initiate signalling cascades (15), 355 
and have been implicated in cancer progression (19). Moreover, their function can be regulated by 356 
their phosphorylation status (56). Therefore, MCPyV ST-induced cell motility was assessed using a 357 
range of concentrations of the integrin inhibitor, RGDS. RGDS is a tetrapeptide that has been 358 
shown to inhibit the binding of ligands to α5β1 and αvβ3 integrins (57). i293-GFP and i293-GFP-ST 359 
cells were induced using doxycycline hyclate, while MCC13 cells were transfected with EGFP or 360 
EGFP-ST. Cells were then treated with non-toxic concentrations of RGDS as measured by a cell 361 
viability (MTS) assay (data not shown)   for a 24-h period prior to imaging using the IncuCyte life 362 
cell imaging system by taking an image every 30 min for a 24-h period (Fig. 7B and D). Distances 363 
travelled by individual cells were analysed and showed decreasing cell motility with increasing 364 
RGDS concentration (Fig. 7C and E). These results therefore suggest a role for integrins, in 365 
MCPyV ST-induced cell motility. 366 
 367 
The activity of integrins is important to MCPyV ST-induced filopodia formation. To 368 
determine whether integrins have an essential role in MCPyV ST-induced filopodia formation. 369 
HEK-293 cells were transfected with EGFP or EGFP-ST, then treated with 100 μM RGDS for 24 h. 370 
Cells then fixed and stained with rhodamine phalloidin to visualise actin-based structures (Fig. 7F), 371 
coupled with quantitative analysis of filopodia (Fig. 7G). Results show that treatment of cells 372 
expressing MCPyV ST with RGDS display fewer filopodia compared to untreated cells expressing 373 
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MCPyV ST alone. These results further implicate a role for integrins in MCPyV ST-induced cell 374 
motility. 375 
 376 
The β1 integrin is dephosphorylated upon MCPyV ST expression. Integrin activity can 377 
be regulated by phosphorylation (56). The importance of integrins in MCPyV ST-induced cell 378 
motility and filopodia formation, revealed above, suggested a possibility that integrin 379 
phosphorylation could be affected by MCPyV ST-PP4C interaction. In particular, the effect of 380 
RGDS on MCPyV ST-induced filopodia formation and cell motility suggested a role for α5β1 and/or 381 
αvβ3. HEK-293 cells do not express αvβ3 (58), thus α5 and/or β1 were of interest. More specifically, 382 
β1 phosphorylation status has been shown to be regulated at the Thr788/789 residues (59). 383 
Therefore, in order to investigate whether MCPyV ST expression had any effect on β1 384 
phosphorylation, HEK-293 cells were transfected with EGFP, EGFP-ST, EGFP-ST102A or EGFP-385 
ST103A. Cell lysates were probed for phosphorylated β1 integrin at Thr788/789. Results showed a 386 
dramatic reduction in the phosphorylation levels of β1 integrin at both these sites upon MCPyV ST 387 
expression. Notably, however, phosphorylation levels remain unchanged upon the expression of 388 
the PP4C-non-binding mutants EGFP-ST102A and EGFP-ST103A (Fig. 8). Densitometry results 389 
confirm that upon MCPyV ST expression, the phosphorylation levels of β1 at Thr788/789 decrease 390 
(Fig. 8A). In contrast, this reduction was inhibited upon the expression of the PP4C transdominant 391 
mutant, PP4-RL (Fig. 8B). These results suggest that the interaction of MCPyV ST and PP4C 392 
leads to reduced β1 integrin phosphorylation levels at Thr788/789, which in turn leads to 393 
downstream signalling that ultimately enhances filopodia formation and cell motility in MCPyV ST-394 
expressing cells.   395 
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DISCUSSION 396 
MCPyV ST is an oncogenic protein, sufficient to transform rodent cells to anchorage- and 397 
contact-independent growth and is also capable of inducing serum-free proliferation of human cells 398 
(33). Moreover, epidermis-targeted coexpression of ST and ATOH1 leads to development of 399 
widespread cellular aggregates, with histology and marker expression mimicking human 400 
intraepidermal MCC, using a panel of preterm transgenic mice.  This supports the concept that ST 401 
is the major MCPyV-derived oncogenic driver in MCC (40). Notably, MCC has a highly metastatic 402 
phenotype which correlates with poor MCC survival rates (41). We have confirmed the existence of 403 
a link between MCPyV ST expression and cell motility and migration, both essential factors for 404 
primary tumour dissemination. Our observation are supported by recent studies showing that 405 
engraftment of MCC cell lines into SCID mice resulted in the appearance of circulating tumour cells 406 
and metastasis formation, with explanted tumours also exhibiting an upregulation of MCPyV ST-407 
Antigen expression in all tumours (42).  408 
Promoting motility and metastasis by virus oncoproteins has been reported previously. 409 
Human papillomavirus 16 (HPV16) E7, Epstein-Barr virus (EBV) EBNA1 and EBNA2, hepatitis B 410 
virus (HBV) X protein, and the SV40 ST have all been shown to induce metastasis, through a 411 
variety of mechanisms including disruption of cellular adhesion, cytoskeletal reorganisation and 412 
gene expression modulation (60-63). The utilisation of the actin cytoskeleton in many viral 413 
processes, including cell transformation, has also been reported (reviewed in (64)).  In this report, 414 
we show that MCPyV ST also affects the actin cytoskeleton. Expression of MCPyV ST drives cell 415 
motility in a multistep process that involves the upregulation of a number of actin-associated 416 
proteins, forming filopodia-like structures, through relocalisation of filopodia-associated proteins.  417 
The interaction of MCPyV ST with Ser/Thr cellular phosphatases PP2A Aα, PP2A Aβ and 418 
PP4C has been well documented (23, 37). Moreover, MCPyV ST interaction with PP4C, seems to 419 
be important in promoting cell motility (43). PP4C has been implicated in apoptosis, DNA mutation, 420 
and cell proliferation (65), as well as a number of cell signalling pathways (66). In addition, it has 421 
been found to be upregulated in some cancers (67) and we have previously reported its 422 
involvement in destabilising the microtubule network to promote cell motility (43). However, this is 423 
the first report of PP4C being implicated in actin dynamics, as MCPyV ST-induced filopodia 424 
formation is dependent upon the interaction.  425 
We report that the Rho-family GTPases appear to be involved in MCPyV ST-induced cell 426 
motility. Other oncogenic viruses have been reported to affect the Rho-family GTPases. The best-427 
known example is SV40 ST, whose activity leads to the rearrangement of filamentous actin 428 
networks, including Rac-induced lamellipodia formation, Cdc42 filopodia formation and loss of 429 
RhoA-dependent stress fibres. Levels of Rac1 and Cdc42 are increased in cells expressing SV40 430 
ST, while levels of RhoA are decreased (63). Thus it is possible that a similar process is occurring 431 
in cells expressing MCPyV ST, except through interaction with PP4C instead of PP2A. Our results 432 
also show that MCPyV ST motility seems to be dependent on Cdc42 and RhoA, as is MCPyV ST-433 
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induced filopodia formation. In addition, phosphorylation has been reported to negatively regulate 434 
the activity of RhoA (68, 69), and to affect the signalling of Cdc42 and Rac1 (70). However, our 435 
results suggest that MCPyV ST-PP4C interaction is not involved in modulating this effect directly.  436 
Finally, we implicate integrins, including β1, in MCPyV ST-induced cell motility and filopodia 437 
formation. Integrins are cellular receptors that are known to be important in cell motility, particularly 438 
in Rho-family GTPase cycling (71). Initially, an integrin inhibitor was used to observe whether 439 
integrins were important in MCPyV ST-specific cell motility. RGDS is a tetrapeptide found on 440 
fibronectin, fibrinogen α, and von Willebrand factor (72, 73), and interacts with α5β1 and αvβ3 441 
integrins (57). Our results indicate that with increasing concentrations of RGDS, a reduction in 442 
MCPyV ST-induced cell motility is observed, and that RGDS also affects MCPyV ST-induced 443 
filopodia formation. We investigated β1 integrin, as it is expressed by HEK-239 cells. A number of 444 
studies have shown the significance of phosphorylation in the activity of integrins, including β1 (56, 445 
59, 74). Whilst he cellular phosphatase PP2A has been shown to dephosphorylate β1 integrin at 446 
Thr788/789 (59), our studies using the transdominant PP4C mutant and specific MCPyV ST 447 
mutants clearly show a role for PP4C. Interestingly, in the absence of MCPyV ST the PP4C 448 
transdominant mutant had no impact on integrin phosphorylation, indicating that PP4C function 449 
maybe specifically redirected in the presence of MCPyV ST. Parallels can be found in the 450 
repurposing of key host factors by virus oncoproteins, for example subversion of E6AP activity by 451 
the HPV E6 protein to ubiquity late cellular p53. Our results show decreased Thr788/789 452 
phosphorylation upon MCPyV ST expression, and that this is dependent on the interaction of 453 
MCPyV ST with PP4C. We thus suggest a mechanism whereupon this interaction leads to the 454 
dephosphorylation of β1 integrin, which in turn activates the cell motility pathway. However, we 455 
cannot rule out the involvement of either other changes in the phosphorylation status of further 456 
integrins or indeed the other β1 integrin phosphorylation sites, including for example S785, which 457 
has been implicated in changes in cell motility in chicken cell lines (74).  458 
Our overall findings suggest a possible mechanism (Fig. 9), whereby the interaction of 459 
MCPyV ST with PP4C leads to the dephosphorylation of one or more integrins, including β1. These 460 
changes may then contribute to the cell motility cascade, through the Rho-family GTPase 461 
modulators, leading to increased filopodia formation and cell motility. These findings highlight the 462 
importance of the MCPyV ST-PP4C interaction in promoting the metastatic phenotype of MCC. 463 
Therefore, this interaction may be a viable drug target. Currently, treatment of MCC depends on 464 
the disease stage, with surgical excision, lymph node dissection and adjuvant radiotherapy being 465 
the standard. Metastasised MCC is treated with various regimens of broad-spectrum 466 
chemotherapy, such as anthracyclines, cyclophosphamide, etoposide, and platinum derivatives, 467 
alone or in combination. Over half of MCC patients respond to chemotherapy, but the median 468 
survival is 21.5 months (75). Potential virus-related drug targets are being identified, particularly for 469 
MCPyV LT and ST. Type I interferon (IFN) reduces LT expression and inhibits cell viability in 470 
MCPyV-positive MCC cell lines (76), but has failed to induce a clinical response in patients (77). In 471 
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adition, YM155, an inhibitor of survivin, a cellular protein upregulated by MCPyV LT important for 472 
the surivival of MCPyV-positive MCC cell lines, has shown a cytostatic effect in MCC xenograft 473 
tumours in mice (78, 79). Finally, the small-molecule tyrosine kinase inhibitor, pazopanib (80), is 474 
currently undergoing phase II clinical trials. The field remains open for novel drugs. 475 
In summary, we describe a novel mechanism by which a human tumour virus induces cell 476 
motility and cancer metastasis, as such it provides new opportunities for therapeutic interventions 477 
for disseminated MCC.  478 
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MATERIALS AND METHODS 479 
Plasmids and antibodies. Expression vectors for EGFP-ST and EGFP-STΔ95-111 have 480 
been previously described (37, 43). EGFP-ST-R7A, EGFP-ST102A and EGFP-ST103A were 481 
produced using the Q5 site directed mutagenesis kit (New England Biolabs) according to the 482 
manufacturer’s protocol and have been previously characterised (50). Sequence verified mutants 483 
were cloned into EGFP using EcoRI and BamHI restriction sites. EGFP-mDia2 was provided by 484 
Shuh Narumiya and pcDNA5-IRSp53-myc was provided by Laura Machesky. Transdominant 485 
mutants pcDNA3-GFP-Cdc42-T17N, pcDNA3-GFP-Rac1-T17N, and pcDNA3-GFP-RhoA-T19N 486 
were purchased from Addgene. MCPyV ST-tagging shRNA plasmids were kindly provided by Dr 487 
Masa Shuda, Pittsburgh. Antibodies for Arp3, cortactin, and cofilin were purchased from Genetex 488 
and used at 1:500 dilution, the p-Cdc42/Rac1 antibody (Cell Signaling Technologies) and the p-β1-489 
Thr788/789 antibody (Abcam), Myosin X (kindly provided by Michelle Peckham, Leeds) were used 490 
at 1:100 dilution, antibodies for Flag, myc and HA (Sigma-Aldrich) and GFP (Living Colours) were 491 
used at 1:5000 dilution. All antibodies used for immunofluorescence were diluted 1:200. 492 
Chemicals. Rho-family GTPase inhibitors ML141 (Sigma Aldrich), NSC23766 (Santa Cruz 493 
Biotech), ZCL278 (Tocris Bioscience), and Rhosin (Merck Milipore) were used at 15M, 50M and 494 
30M in i293-GFP and i293-GFP-ST and at 30 μM, 75 μM and 60 μM in MCC13s. The integrin 495 
inhibitor RGDS (Tocris Bioscience) was used at a range of concentrations (see Results) on both 496 
293-derived cells and MCC13 cells. Cell toxicity was measured using a MTS-based CellTiter 96 497 
AqueousOne Solution Proliferation assay (Promega), as previously described (81). 498 
Mammalian cell culture. HEK-293 Flip-In cell line was purchased from Invitrogen. i293-ST 499 
(37), i293-GFP, and i293-GFP-ST cell lines were derived from HEK-293 Flip-Ins using 500 
manufacturer’s protocol as previously described (37). HEK-293s (ECACC) and derivative cells 501 
were grown in 10% were maintained in Dulbecco’s modified Eagle’s medium (DMEM) containing 502 
10% foetal bovine serum (FBS) and 1% penicillin/streptomycin as previously described (82). The 503 
MCPyV positive MCC cell lines, WaGa, was grown in RPMI 1640 (Sigma) supplemented with 10% 504 
FBS. MCC13 cell line (ECACC) were maintained in RPMI 1640 media supplemented with 15% 505 
FBS and 1% penicillin/streptomycin. Primary normal human epidermal keratinocytes (Promocell) 506 
were cultured in serum free keratinocyte media (Gibco 17005-34) with 5ng/ml EGF supplemented. 507 
Primary Normal Adult Dermal Fibroblast cells (ATCC) were cultured using a Fibroblast Growth Kit–508 
Serum-Free kit (ATCC). ST-FLAG, EGFP and EGFP-ST expression was induced from i293-ST 509 
[34], i293-GFP, and i293-GFP-ST cells respectively with 2 μg/ml Doxycycline hyclate for up to 48 510 
hours. Cells were plated into 6-well plates and transfections routinely used 1 μg plasmid DNA and 511 
Lipofectamine 2000 (Life Technologies) or 5 μg plasmid DNA and nucleofection (Lonza) following 512 
the manufacturer’s instructions. 513 
Multicolour immunohistochemistry. Formalin-fixed, paraffin-embedded (FFPE) sections 514 
from primary MCC tumours were purchased from Origene and analysed as previously described 515 
(83). Primary antibodies were: CK20 (Dako, dilution 1:50), MCPyV LTA CM2B4 (Santa Cruz 516 
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Biotechnology, dilution 1:125) and Anti-Cortactin (Abcam, dilution 1:250). An isotype-matched 517 
irrelevant antibody was used as a negative control on sections of tissues in parallel, a rabbit 518 
polyclonal isotype control antibody (Abcam) was used to match the cortactin primary antibody. 519 
Sections were incubated with appropriate secondary antibodies labelled with different 520 
fluorochromes (Alexa Fluor 488 IgG2B, 633 IgG2A, Invitrogen, and IgG (H+L)-TRITC, Jackson 521 
ImmunoResearch). All slides were mounted with Immuno-Mount and images were captured with a 522 
Zeiss LSM 510 confocal microscope. 523 
Immunoprecipitation assays and Immunoblotting. Co-immunoprecipitations, in addition 524 
to subsequent protein analysis by SDS-PAGE and western blot, were performed as previously 525 
described (84). Tumour and skin samples were homogenised in 5 volumes of suspension buffer 526 
(0.1M NaCl, 10mM Tris.Cl [pH 8.0], 1mM EDTA and 0.1 mg/ml AEBSF protease inhibitor [Roche, 527 
Germany]), as previously described (85).  In contrast, cells were lysed in a modified RIPA buffer 528 
(50 mM Tris-HCl pH 7.6, 150 mM NaCl, 1% NP40), supplemented with protease inhibitor cocktail 529 
(Roche) [73]. For phosphorylation studies, cells were lysed in a modified buffer (20 MM Tris-HCl 530 
pH 7.4, 150 mM NaCl, 50 mM NaF, 5 mM Na4O7P2B, 1 mM EDTA, 1 mM Ta3VO4, 10% glycerol, 531 
1% Triton). Proteins were separated by SDS-PAGE, before transfer onto nitrocellulose membrane 532 
(Hybond C extra, Amersham Biosciences). Membranes were probed with the appropriate primary 533 
and HRP-conjugated secondary antibodies. Proteins were detected using EZ-ECL enhancer 534 
solution (Geneflow) as previously described [74]. Densitometry was performed using ImageJ 535 
software. 536 
Live cell imaging. Cell motility was analysed using an Incucyte kinetic live cell imaging 537 
system as directed by the manufacturer. HEK293 cells or i293-GFP/i293-GFP-ST cells were 538 
seeded at a density of 25,000 cells per well of a 6 well plate, MCC13 cells were seeded at a 539 
density of 100,000 cells per well of a 6 well plate. After 12h, the cells were transfected with 1 μg of 540 
DNA per well and/or induced using doxycycline hyclate. For transfected cells, media was changed 541 
after 6h (HEK-293 or derivatives) or 12h (MCC13). If appropriate, cells were treated with inhibitors 542 
for 24h pre-imaging. Imaging was performed for a 24h period, with images taken every 30 minutes. 543 
Cell motility was then tracked and analysed using ImageJ software. 544 
Immunofluorescence. Immunofluorescence was carried out as previously described (86). 545 
If appropriate, cells were treated with inhibitors for 24h pre-fixing. Cells were viewed on a Zeiss 546 
LSM700 confocal microscope under an oil-immersion 63x objective lens. Images were analysed 547 
using the LSM imaging software. Filopodia were counted using ImageJ software. 548 
  Activation Assay for RhoA and Cdc42. The activation of RhoA or cdc42 was determined 549 
using pull-down assays for activated RhoA or activated cdc42, as previously described (87), using 550 
RhoA and cdc42 Activation Assay kits (Cell Biolabs), as directed by the manufacturer’s instructions. 551 
For the analysis of RhoA activation, cell lysates were incubated with Rhotekin RBD Agarose beads, 552 
which have a high affinity for GTP-RhoA. For the analysis of cdc42 activation, cell lysates were 553 
incubated with PAK1 PBD Agarose beads, which have a high affinity for GTP-cdc42. Affinity-554 
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precipitated activated GTP-bound RhoA or cdc42 levels were then analysed by immunoblotting 555 
using RhoA and cdc42-specific antibodies. 556 
qRT-PCR. RNA was extracted from uninduced and induced i293-ST cells using TRIzol 557 
(Invitrogen) (88). RNA was DNase treated using the Ambion DNase-free kit, as per the 558 
manufacturer’s instructions, and RNA (1μg) from each fraction was reverse transcribed with 559 
SuperScript II (Invitrogen), as per the manufacturer’s instructions, using oligo(dT) primers 560 
(Promega). 10ng of cDNA was used as template in SensiMixPlus SYBR qPCR reactions 561 
(Quantace), as per manufacturer’s instructions, using a Rotor-Gene Q 5plex HRM Platform 562 
(Qiagen), with a standard 3-step melt program (95 ̊C for 15 seconds, 60 C̊ for 30 seconds, 72 ̊C for 563 
20 seconds) as previously described (89). With GAPDH as internal control mRNA, quantitative 564 
analysis was performed using the comparative ΔΔcT method as previously described (90). 565 
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FIGURE LEGENDS 815 
 816 
FIGURE 1. MCPyV ST expression results in the upregulation of several actin-associated proteins. 817 
(A) (i) i293-ST cells remained uninduced or were incubated for 48 h in the presence of doxycycline 818 
hyclate or (ii) MCC13 cells were transfected with 1 g EGFP or EGFP-ST for 12 h. Cell lysates 819 
were then probed with Arp3-, cortactin- and cofilin-specific antibodies. GAPDH was used as a 820 
measure of equal loading, the 2T2 hybridoma was used to confirm MCPyV ST expression. (B) 821 
Densitometry quantification of the western blots was carried out using the Image J software and is 822 
shown a percentage of relative densitometry to the loading control, GAPDH (n=3). (C) Total RNA 823 
was extracted from uninduced or induced i293-ST cells after 24 hours and relative transcript levels 824 
analysed by qRT-PCR using GAPDH as a reference.  Fold increase was determined by ΔΔcT and 825 
statistical significance analysed using a non-paired t-test.  Data from 3 independent experiments is 826 
presented as fold increase versus uninduced control, * = p<0.001. (D) FFPE sections of two 827 
primary MCC tumours were stained with CK20, MCPyV LT and cortactin-specific antibodies or an 828 
isotype negative control. Sections were then incubated with Alexa Fluor-labelled secondary 829 
antibodies and analysed using a Zeiss LSM 510 confocal laser scanning microscope. (E) 830 
Immunoblot analysis was performed on the cellular lysates of two independent MCC tumour 831 
samples and a negative control non-tumour cadaveric skin sample using Arp3- and cortactin-832 
specific antibodies. GAPDH was used as a measure of equal loading, the 2T2 hybridoma was 833 
used to confirm MCPyV ST expression. (F) Densitometry quantification of the western blots was 834 
carried out using the Image J software and is shown a percentage of relative densitometry to the 835 
loading control, GAPDH. Data analysed using three replicates per experiment, n=3 and statistical 836 
analysis using a two-tailed t-test with unequal variance, * = p<0.01. (G) The MCPyV-positive MCC 837 
cell line was transduced with lentivirus expressing a scramled shRNA or ST-targetting shRNA. 838 
Upon ST depletion cell lysates were probed with Arp3- and cortactin-specific antibodies. GAPDH 839 
was used as a measure of equal loading, the 2T2 hybridoma was used to confirm MCPyV ST 840 
expression. (H) Densitometry quantification of the western blots was carried out using the Image J 841 
software and is shown a percentage of relative densitometry to the loading control, GAPDH (n=3). 842 
 843 
FIGURE 2. MCPyV ST expression results in an increase in the numbers and length of actin-based 844 
protrusions. (A) HEK-293  (B) MCC13 (E) Primary Epidermal keratinocytes (G) Primary Dermal 845 
Fibroblast cells were transfected with 1-5 g of either EGFP or EGFP-ST. Cells were fixed after 24 846 
h and stained with rhodamine-phalloidin. Slides were then analysed using a Zeiss LSM 700 847 
confocal laser scanning microscope. (C), (D), (F) and (H) The number and length of actin-based 848 
protrusions in each cell line were analysed for 100 cells per condition using ImageJ software. 849 
Protrusion length is presented as a percentage of total number of protrusions.  850 
 851 
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FIGURE 3. Screening of actin-associated proteins suggests MCPyV ST expression induces 852 
filopodia formation. (A) HEK-293 cells were co- transfected with 1 g of EGFP-mDia2 and empty 853 
control vector or co-transfected with 1 g of EGFP-mDia2 and ST-Flag. 24 h later, cells were fixed, 854 
permeabilised and GFP fluorescence analysed by direct visualisation, in addition cells were 855 
stained with rhodamine-phalloidin and a Flag-specific antibody. (B) HEK-293 cells were co-856 
transfected with 1 g of EGFP and IRSp53-myc or co-transfected with 1 g of EGFP-ST and 857 
IRSp53-myc. 24 h later cells were fixed, permeabilised and GFP fluorescence analysed by direct 858 
visualisation, in addition cells were stained with rhodamine-phalloidin and a Myc-specific antibody. 859 
(C) HEK-293 cells were transfected with 1 g of EGFP or EGFP-ST. 24 h later cells were fixed, 860 
permeabilised and GFP fluorescence analysed by direct visualisation, in addition cells were 861 
stained with rhodamine-phalloidin and a Myosin X-specific antibody. The expanded box shows 862 
myosin X-staining at the tips of filopodia. All slides were analysed using a Zeiss LSM 700 confocal 863 
laser scanning microscope. 864 
 865 
FIGURE 4. MCPyV ST interaction with cellular phosphatases is required for  filopodia formation. 866 
(A) HEK-293 cells were transfected with 1 g EGFP, EGFP-ST, EGFP R7A, EGFP-STΔ95-111, 867 
EGFP-ST102A or EGFP-ST103A. 24 h later cells were fixed and GFP fluorescence analysed by 868 
direct visualisation, in addition cells were stained with rhodamine-phalloidin. All slides were 869 
analysed using a Zeiss LSM 700 confocal laser scanning microscope. (B) The number and length 870 
of actin-based protrusions were analysed for 50 cells per condition using ImageJ software. 871 
Protrusion length is presented as a percentage of total number of protrusions.  (C) HEK-293 cells 872 
were transfected with 1 g of EGFP, EGFP-ST, EGFP-STΔ95-111, EGFP-ST102A or EGFP-873 
ST103A. 24 h later cell lysates were incubated for either GFP-TRAP agarose beads. Pulldowns 874 
were then immunoblotted with PP2A Aβ and PP4C-specific antibodies. A GFP-specific antibody 875 
was used to confirm the expression of the EGFP-tagged MCPyV ST constructs. (D) HEK 293 cells 876 
or MCC13 cells were transfected with 1 g EGFP, EGFP-ST, EGFP-ST102A or EGFP-ST103A. 877 
After 24 h, cell motility was analysed using an Incucyte kinetic live cell imaging system. Images 878 
were taken for 30 minutes for a 24 hour period. Movement is represented as average distance 879 
travelled compared to control EGFP-transfected cells was measured in μM (n=25 per condition) 880 
and significance was tested using a 3-tailed Student’s t-test, * = p<0.01. (E) HEK-293 cells were 881 
transfected with 1 g of EGFP or EGFP-ST in the absence or presence of the PP4C transdominant 882 
mutant, PP4-RL. 24 h later cells were permeabilised, fixed and GFP fluorescence analysed by 883 
direct visualisation, in addition cells were stained with rhodamine-phalloidin and  an HA-tag-specific 884 
antibody. All slides were analysed using a Zeiss LSM 700 confocal laser scanning microscope. (F) 885 
The number and length of actin-based protrusions were analysed for 50 cells per condition using 886 
ImageJ software. Protrusion length is presented as a percentage of total number of protrusions. 887 
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FIGURE 5. Live cell imaging shows a dependence of MCPyV ST-induced cell motility on Cdc42 889 
and RhoA. (A) i293-EGFP and i293-EGFP-ST cells were induced using doxycycline hyclate or (C) 890 
MCC13 cells were transfected with 1g of EGFP and EGFP-ST. Cells were then treated with 1 891 
g/l DMSO, 15 M of ML141, 50 M of NSC23766 or ZCL278, or 30 M of Rhosin. After 24 h, 892 
cell motility was analysed using an Incucyte kinetic live cell imaging system. Images were taken for 893 
30 minutes for a 24 hour period. The movement of cells were then tracked using Image J software. 894 
(B) and (D) The average distance travelled was measured in μm (n=25 per condition) and 895 
significance was tested using a 3-tailed Student’s t-test, * = p<0.01. 896 
 897 
FIGURE 6. MCPyV ST-induced filopodia formation is dependent on the activity of Rho-family 898 
GTPases. (A) HEK-293 cells were transfected with 1 g EGFP or EGFP-ST and treated with 1 899 
g/l DMSO, 15 M of ML141, 50 M of NSC23766 or ZCL278, or 30 M of Rhosin 24 h. After 24 900 
h cells were fixed and GFP fluorescence analysed by direct visualisation, in addition cells were 901 
stained with rhodamine-phalloidin. (C) HEK-293 cells were transfected with 1 g EGFP-ST or co-902 
transfected with 1 g ST-Flag and pcDNA5-GFP-Cdc42-T17N,  pcDNA5-GFP-Rac1-T17N, or 903 
pcDNA5-GFP-RhoA-T19N. 12 hours later cells were fixed, permeabilised and stained with 904 
rhodamine-phalloidin and a Flag-specific antibody. All slides were analysed using a Zeiss LSM 700 905 
confocal laser scanning microscope. (B) and (D) The number and length of actin-based protrusions 906 
were analysed for 50 cells per condition using ImageJ software. Protrusion length is presented as 907 
a percentage of total number of protrusions. (E) HEK-293 cells were transfected with 1 g EGFP or 908 
EGFP-ST and after 24 hours cell lysates were incubated with either PAK1 PBD or Rhotekin RBD 909 
Agarose beads. Pulldowns were then immunoblotted with Cdc42 and RhoA-specific antibodies and 910 
the 2T2 hybridoma was used to confirm MCPyV ST expression. 911 
 912 
FIGURE 7. Integrin inhibitor RGDS reduces MCPyV ST-induced cell motility and filopodia 913 
formation. (A) i293-GFP or i293-GFP-ST were transfected with 1 g HA-Cdc42 or HA-Rac1 and 914 
then induced with doxycyline hyclate and for 6 h. Cell lysates were probed for phosphorylated 915 
Cdc42/Rac1 at the S71 residue. HA-tag and GAPDH-specific antibodies were used to measure 916 
equal loading. 2T2 was used to probe for MCPyV ST expression. (B) i293-EGFP and i293-EGFP-917 
ST cells were induced using doxycycline hyclate or (D) MCC13 cells were transfected with 1g of 918 
EGFP and EGFP-ST. After 24 hours cells were treated with 1 g/l DMSO or 1 M, 10 M, 50 M, 919 
or 100 M RGDS. After 24 h, cell motility was analysed using an Incucyte kinetic live cell imaging 920 
system. Images were taken for 30 minutes for a 24 hour period. The movement of cells were then 921 
tracked using Image J software. (C) and (E) The average distance travelled was measured in μm 922 
(n=25 per condition) and significance was tested using a 3-tailed Student’s t-test, p<0.001. (F) 923 
HEK-293 cells were transfected with 1 g EGFP or EGFP-ST, then treated with 100 μM RGDS. 924 
After 24 h cells were fixed and GFP fluorescence analysed by direct visualisation, in addition cells 925 
 o
n
 N
ovem
ber 6, 2017 by guest
http://jvi.asm.org/
D
ow
nloaded from
 
27 
 
were stained with rhodamine-phalloidin. (G) The number and length of actin-based protrusions 926 
were analysed for 50 cells per condition using ImageJ software. Protrusion length is presented as 927 
a percentage of total number of protrusions. 928 
 929 
FIGURE 8. MCPyV ST expression reduces the phosphorylation levels of β1 integrin at Thr 788/789 930 
residues. (A) (i) HEK-293 cells were transfected with 1 g EGFP, EGFP-ST, EGFP-ST102A or 931 
EGFP-ST103A. After 24 hours, cell lysates were probed for phosphorylated Thr 788/789 residues 932 
of β1 integrin. GAPDH was used to measure equal loading. 2T2 was used to probe for MCPyV ST 933 
expression. (ii) Densitometry quantification of the western blots was carried out using the Image J 934 
software and is shown a percentage of relative densitometry to the loading control, GAPDH. Data 935 
analysed using three replicates per experiment, n=3 and statistical analysis using a two-tailed t-test 936 
with unequal variance, * = p<0.01. (B) (i) HEK-293 cells were transfected with 1 g EGFP, EGFP-937 
ST in the absence or presence of PP4C transdominant mutant, PP4-RL. After 24 hours, cell 938 
lysates were probed for phosphorylated Thr 788/789 residues of β1 integrin. GAPDH was used to 939 
measure equal loading. 2T2 was used to probe for MCPyV ST expression. (ii) Densitometry 940 
quantification of the western blots was carried out using the Image J software and is shown a 941 
percentage of relative densitometry to the loading control, GAPDH. Data analysed using three 942 
replicates per experiment, n=3 and statistical analysis using a two-tailed t-test with unequal 943 
variance, * = p<0.01. 944 
 945 
FiGURE 9. Schematic representation of MCPyV ST-induced cell motility. The MCPyV ST-PP4C 946 
interaction leads to the dephosphorylation of β1 integrin. This change in phosphorylation status 947 
leads to the initiation of the cell motility pathway, mediated via the Rho-family GTPases. 948 
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